Respiratory Disorders

Dupilumab Studies Show Benefit in Chronic Rhinosinusitis With Nasal Polyps

By October 16, 2018

In both studies, at 24 weeks, patients treated with dupilumab plus corticosteroid nasal spray experienced a 51% and 57% improvement in nasal congestion/obstruction severity vs 15% and 19% improvement with nasal spray alone.

High Flow Nasal Cannula Oxygen Therapy May Benefit Elderly Patients in ICU

October 12, 2018

After high flow nasal cannula oxygen therapy, 15% of patients had to be intubated and mechanically ventilated, but the majority stepped down to regular oxygen therapy.

Metered Dose Inhaler Errors Affect Many With COPD, Asthma

October 12, 2018

The most common error related to the use of metered dose inhalers was the failure to attach the inhaler to a spacer.

Cardiovascular Safety of Revefenacin as COPD Treatment Examined

October 12, 2018

No changes were observed in 12-lead electrocardiographic recordings associated with daily doses of revefenacin 88 μg and 175 μg in patients with COPD.

Opioid Use Increases Likelihood of Intubation in COPD

October 12, 2018

Patients with chronic obstructive pulmonary disease who used opioids were more likely to be intubated during their hospitalization compared with nonopioid users

Lung Function Improved With Dupilumab in Adolescents With Asthma

October 12, 2018

Adolescents with asthma treated with dupilumab experienced significant improvements in FEV1 compared with placebo.

Pirfenidone Effective for Improving Pulmonary Fibrosis Symptoms

October 12, 2018

When treated with pirfenidone, patients with idiopathic pulmonary fibrosis experienced significant improvements in 6-minute walking distance and University of California San Diego Shortness of Breath Questionnaire scores.

Montelukast Plus Levocetirizine vs Monotherapy in Asthma, Allergic Rhinitis

October 12, 2018

Montelukast plus levocetirizine demonstrated a significant reduction in mean daytime nasal symptom scores compared with montelukast monotherapy.

Beta-Blockers Safe in COPD With Cardiovascular Comorbidities

October 12, 2018

There was a trend toward a reduction in mortality in patients with COPD who received beta-blocker treatment compared with patients who did not.

Severe Eosinophilic Asthma Effectively Managed With Benralizumab

October 12, 2018

Benralizumab was associated with a significant reduction in annual asthma exacerbation rates.

Stiolto Respimat Labeling Updated With COPD Exacerbation Data, Revised Indication

By October 11, 2018

In addition to the new exacerbation data, the indication for Stiolto Respimat has been revised.

Novel Inhaled Treatment for Cystic Fibrosis Granted Orphan Drug Designation

By October 11, 2018

SNSP113 is intended to improve lung function in CF patients by targeting key drivers of pulmonary decline such as infection, airway congestion and inflammation.

Aclidinium Bromide May Increase MACE Risk in Those With CV Risk Factors

October 11, 2018

Major cardiovascular adverse events were more common in the previous event subgroup, with 5.5% occurring in the aclidinium group and 6.2% in the placebo group.

Inhaled Corticosteroid Therapy Refill Disruption Leads to Exacerbations

October 11, 2018

Disrupting regular combination inhaled corticosteroid therapy refills increased hospitalizations and exacerbations.

Red Tide May Be Cause of Florida Beachgoers' Breathing Problems

October 04, 2018

People who develop symptoms should leave the beach and find someplace cool.

Nuzyra Approved for CABP, Acute Skin/Skin Structure Infections

By October 03, 2018

The approval was based on Phase 3 data from 2 studies in ABSSSI, where treatment with Nuzyra was compared with linezolid, and 1 study in CABP comparing Nuzyra with moxifloxacin. Across all 3 trials, Nuzyra was found to be effective and generally safe and well-tolerated.

Telemedicine RTI Visits Shorter When Antibiotic Prescribed

October 02, 2018

"Because telemedicine encounters are short and physicians are often reimbursed by encounter volume, antibiotic stewardship efforts that lengthen visits even slightly may be challenging to implement," the authors write.

Arikayce Approved to Treat <i>Mycobacterium Avium</i> Complex Lung Disease

By October 01, 2018

Arikayce is intended for oral inhalation use and is administered via the Lamira Nebulizer System only.

Xolair Prefilled Syringe Formulation Gets FDA Approval

By October 01, 2018

The PFS formulation eliminates the need to reconstitute the solution before administration.

Nintedanib Plus Sildenafil No Better Than Nintedanib in IPF

September 28, 2018

The researchers found that there was no significant difference between the nintedanib-plus-sildenafil group and the nintedanib group in terms of the adjusted mean change from baseline in the SGRQ total score at week 12 (−1.28 and −0.77 points, respectively; P=.72).

Chronic Obstructive Pulmonary Disease Treatments

September 27, 2018

List of FDA-approved medications used for the maintenance and treatment of chronic obstructive pulmonary disease (COPD).

Does Milk Consumption Increase Mucus Production?

September 24, 2018

Patients perceive swallowing difficulty from thickness of saliva, but no real increase in mucus

Eosinophilic Asthma Treatment: Biologic Agents Compared

By September 21, 2018

PubMed was searched to obtain data on the relative efficacies of benralizumab, dupilumab, lebrikizumab, mepolizumab, reslizumab, and tralokinumab.

Low Vitamin D Levels Tied to Interstitial Lung Disease

September 21, 2018

There was an association between 25(OH)D deficiency and increased prevalence of interstitial lung abnormalities 10 years later.

Infant PPI Use and Lung Infection Risk: Is There a Link?

By September 20, 2018

The data showed matched odds ratio for current vs past use of PPIs to be 0.88 (95% CI, 0.36 to 2.16) when comparing cases and their controls for community-acquired pneumonia. With regard to lower respiratory tract infections, the matched odds ratio between cases and their controls was 1.13 (95% CI, 0.87 to 1.48).

Benralizumab Efficacy Maintained in Long-Term Severe Eosinophilic Asthma Study

By September 19, 2018

Results from the extension trial showed a similar safety and tolerability profile for Fasenra as that seen in SIROCCO and CALIMA.

Revefenacin Cuts COPD Exacerbation Rates in Phase 3 Studies

By September 18, 2018

Pooled data from two identical 12-week pivotal Phase 3 trials (N=1229) in patients with moderate to very severe COPD showed that the mean annualized rate of all COPD exacerbations was 0.47, 0.45, and 0.55 for revefenacin 175mcg/day, 88mcg/day, and placebo, respectively.

Factors Predictive of Escalated Care in Infant Bronchiolitis ID'd

September 18, 2018

Multivariable predictors included oxygen saturation <90%, nasal flaring and/or grunting, apnea, retractions, age ≤2 months, dehydration, and poor feeding (odds ratios, 8.9, 3.8, 3.0, 3.0, 2.1, 2.1, and 1.9, respectively).

Ofev Slows Idiopathic Pulmonary Fibrosis Progression Long-Term

By September 17, 2018

The primary objective was to characterize the long-term safety and tolerability of Ofev in patients with IPF; efficacy endpoints included annual rate of decline in forced vital capacity (FVC) calculated over 192 weeks.

Ambient Particulate Matter Linked to Emergency Asthma Care

September 17, 2018

Asthma hospital visits increased by 16.8 and 65.8% when the 3-day average exceeded 50µg/m³ and 100µg/m³, respectively.